Project documents | Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18] | Guidance

Documents

Documents created during the development process.

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): update to stakeholders

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): update to stakeholders
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): update to stakeholders (PDF 35 KB)

Published:

18 February 2009

Rheumatoid arthritis - adalimumab, etanercept and infliximab: letter to consultees and commentators regarding the appeal panel's decision

Rheumatoid arthritis - adalimumab, etanercept and infliximab: letter to consultees and commentators regarding the appeal panel's decision
Rheumatoid arthritis - adalimumab, etanercept and infliximab: letter to consultees and commentators regarding the appeal panel's decision (PDF 38 KB)

Published:

24 November 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab: appeal panel's decision

Rheumatoid arthritis - adalimumab, etanercept and infliximab: appeal panel's decision information
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal panel's decision
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal panel's decision (PDF 146 KB)

Published:

21 November 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal announcement

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal announcement
Abbot Laboratories Ltd
Appeals received
Appeals received (PDF 44 KB)

Published:

29 September 2008
Initial scrutiny letter
Initial scrutiny letter (PDF 83 KB)

Published:

29 September 2008
Response to scrutiny letter
Response to scrutiny letter (PDF 312 KB)

Published:

29 September 2008
Final scrutiny letter
Final scrutiny letter (PDF 35 KB)

Published:

29 September 2008
Arthritis and Musculoskeletal Alliance (ARMA)
Appeals received
Appeals received (PDF 123 KB)

Published:

29 September 2008
Initial scrutiny letter
Initial scrutiny letter (PDF 79 KB)

Published:

29 September 2008
Response to scrutiny letter
Response to scrutiny letter (PDF 123 KB)

Published:

29 September 2008
Final scrutiny letter
Final scrutiny letter (PDF 97 KB)

Published:

29 September 2008
National Rheumatoid Arthritis Society (NRAS)
Appeals received
Appeals received (PDF 372 KB)

Published:

29 September 2008
Initial scrutiny letter
Initial scrutiny letter (PDF 116 KB)

Published:

29 September 2008
Response to scrutiny letter
Response to scrutiny letter (PDF 153 KB)

Published:

29 September 2008
Final scrutiny letter
Final scrutiny letter (PDF 96 KB)

Published:

29 September 2008
Royal College of Nursing (RCN)
Appeals received
Appeals received (PDF 114 KB)

Published:

29 September 2008
Initial scrutiny letter
Initial scrutiny letter (PDF 91 KB)

Published:

29 September 2008
Response to scrutiny letter
Response to scrutiny letter (PDF 24 KB)

Published:

29 September 2008
Final scrutiny letter
Final scrutiny letter (PDF 66 KB)

Published:

29 September 2008
Schering- Plough Ltd
Appeals received
Appeals received (PDF 597 KB)

Published:

29 September 2008
Final scrutiny letter
Final scrutiny letter (PDF 59 KB)

Published:

29 September 2008
Wyeth Pharmaceuticals
Appeals received
Appeals received (PDF 705 KB)

Published:

29 September 2008
Initial scrutiny letter
Initial scrutiny letter (PDF 240 KB)

Published:

29 September 2008
Response to scrutiny letter
Response to scrutiny letter (PDF 677 KB)

Published:

29 September 2008
Final scrutiny letter
Final scrutiny letter (PDF 88 KB)

Published:

29 September 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final appraisal determination

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final appraisal determination
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final appraisal determination information
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final appraisal determination (PDF 234 KB)

Published:

21 July 2008
Response to consultee, commentator and public comments on the ACD and comments from website consultation
Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 317 KB)

Published:

21 July 2008
Consultee and commentator comments on the ACD
Abbott Laboratories
Abbott Laboratories (PDF 79 KB)

Published:

21 July 2008
Arthritis and Musculoskeletal Alliance (ARMA) - submission and letters supporting submission from Arthritis Care, BSR, NRAS and RCN
Arthritis and Musculoskeletal Alliance (ARMA) - submission and letters supporting submission from Arthritis Care, BSR, NRAS and RCN (PDF 305 KB)

Published:

21 July 2008
Arthritis Care
Arthritis Care (PDF 55 KB)

Published:

21 July 2008
Department of Health
Department of Health (PDF 12 KB)

Published:

21 July 2008
National Rheumatoid Arthritis Society (including comments from members)
National Rheumatoid Arthritis Society (including comments from members) (PDF 397 KB)

Published:

21 July 2008
NHS Quality Improvement Scotland
NHS Quality Improvement Scotland (PDF 16 KB)

Published:

21 July 2008
Roche
Roche (PDF 44 KB)

Published:

21 July 2008
Royal College of Nursing
Royal College of Nursing (PDF 22 KB)

Published:

21 July 2008
Schering-Plough
Schering-Plough (PDF 177 KB)

Published:

21 July 2008
Somerset PCT
Somerset PCT (PDF 11 KB)

Published:

21 July 2008
Welsh Assembly Government
Welsh Assembly Government (PDF 12 KB)

Published:

21 July 2008
Wyeth Pharmaceuticals
Wyeth Pharmaceuticals (PDF 222 KB)

Published:

21 July 2008
NICE Guideline Development Group
NICE Guideline Development Group (PDF 51 KB)

Published:

21 July 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appraisal consultation

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): evaluation report
Overview
Summary of the documents presented to the Committee
Summary of the documents presented to the Committee (PDF 106 KB)

Published:

29 April 2008
Overview information
Overview (PDF 321 KB)

Published:

29 April 2008
Decision Support Unit reports
Modelling the Cost Effectiveness of Sequential Use of the TNF Inhibitors in the Management of Rheumatoid Arthritis: An Update
Modelling the Cost Effectiveness of Sequential Use of the TNF Inhibitors in the Management of Rheumatoid Arthritis: An Update (PDF 264 KB)

Published:

29 April 2008
The Sequential use of TNF-alpha inhibitors, prepared by Dr Allan Wailoo (School of Health and Related Research, University of Sheffield) for the NICE Decision Support Unit
The Sequential use of TNF-alpha inhibitors, prepared by Dr Allan Wailoo (School of Health and Related Research, University of Sheffield) for the NICE Decision Support Unit (PDF 395 KB)

Published:

29 April 2008
The Effectiveness of Non Biologic DMARDs After Anti TNF-alpha Inhibitor Failure information
The Effectiveness of Non Biologic DMARDs After Anti TNF-alpha Inhibitor Failure (PDF 205 KB)

Published:

29 April 2008
Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients information
Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients (PDF 486 KB)

Published:

29 April 2008
Sequential TNF-alpha Inhibitors and Non Biologic DMARDs - Analysis of the National Databank for Rheumatic Diseases information
Sequential TNF-alpha Inhibitors and Non Biologic DMARDs - Analysis of the National Databank for Rheumatic Diseases (PDF 171 KB)

Published:

29 April 2008
Consultee and Commentator comments information
Abbott Laboratories
Abbott Laboratories (PDF 306 KB)

Published:

29 April 2008
British National Formulary
British National Formulary (PDF 17 KB)

Published:

29 April 2008
British Society for Rheumatology
British Society for Rheumatology (PDF 198 KB)

Published:

29 April 2008
Department of Health
Department of Health (PDF 13 KB)

Published:

29 April 2008
National Rheumatoid Arthritis Society
National Rheumatoid Arthritis Society (PDF 26 KB)

Published:

29 April 2008
Royal College of Nursing
Royal College of Nursing (PDF 23 KB)

Published:

29 April 2008
Schering-Plough
Schering-Plough (PDF 144 KB)

Published:

29 April 2008
Wyeth Pharmaceuticals
Wyeth Pharmaceuticals (PDF 119 KB)

Published:

29 April 2008
A clinical advisor to the Assessment Group
A clinical advisor to the Assessment Group (PDF 12 KB)

Published:

29 April 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): notification of decision to split the FAD

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): notification of decision to split the FAD
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): notification of decision to split the FAD (PDF 18 KB)

Published:

02 January 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal panel decision

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal panel decision
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal panel decision (PDF 131 KB)

Published:

12 June 2007

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final scope

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final scope
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final scope (PDF 112 KB)

Published:

26 November 2004